MEI Pharma Inc - Asset Resilience Ratio
MEI Pharma Inc (MEIP) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MEI Pharma Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how MEI Pharma Inc's Asset Resilience Ratio has changed over time. See MEI Pharma Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MEI Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MEIP market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: MEI Pharma Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
MEI Pharma Inc Industry Peers by Asset Resilience Ratio
Compare MEI Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for MEI Pharma Inc (2005–2025)
The table below shows the annual Asset Resilience Ratio data for MEI Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | $0.00 | $18.29 Million | -- |
| 2024-06-30 | 83.72% | $34.64 Million | $41.38 Million | +14.37pp |
| 2023-06-30 | 69.35% | $83.79 Million | $120.81 Million | -7.97pp |
| 2022-06-30 | 77.32% | $137.51 Million | $177.84 Million | -5.90pp |
| 2021-06-30 | 83.22% | $144.88 Million | $174.10 Million | +2.02pp |
| 2020-06-30 | 81.20% | $170.30 Million | $209.73 Million | +2.69pp |
| 2019-06-30 | 78.51% | $64.90 Million | $82.66 Million | -6.94pp |
| 2018-06-30 | 85.45% | $89.43 Million | $104.66 Million | +4.48pp |
| 2017-06-30 | 80.98% | $45.11 Million | $55.70 Million | +6.60pp |
| 2016-06-30 | 74.38% | $35.08 Million | $47.16 Million | +4.79pp |
| 2015-06-30 | 69.59% | $45.06 Million | $64.75 Million | -0.72pp |
| 2014-06-30 | 70.30% | $35.02 Million | $49.81 Million | -- |
| 2013-06-30 | 0.00% | $0.00 | $36.55 Million | -- |
| 2012-06-30 | 0.00% | $0.00 | $6.37 Million | -- |
| 2005-06-30 | 51.64% | $10.00 Million | $19.36 Million | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more